What is the overarching aim of EO 13944 and related acts?

• A. To accelerate outsourcing of US drug manufacturing
• B. To promote import of foreign medicines regardless of origin
• C. To strengthen U.S. manufacturing of essential medicines and related inputs
• D. To privatize the FDA

Answer: (C)

The key idea is to boost national resilience by building and sustaining domestic production for essential medicines and the ingredients that go into them, so the United States isn’t overly exposed to disruptions in foreign supply chains. EO 13944 focuses on identifying critical drugs and drug inputs (like APIs and excipients), assessing where vulnerabilities exist, and encouraging investment in U.S. manufacturing, supplier diversification, and related infrastructure. This emphasis on domestic capacity directly supports reliable, timely access to required medicines, even during shortages or emergencies. That’s why the option about strengthening U.S. manufacturing of essential medicines and related inputs is the best fit. It’s not about outsourcing, importing regardless of origin, or privatizing the FDA.